U.S. Department of Health & Human Services Divider Arrow National Institutes of Health Divider Arrow NCATS

Details

Stereochemistry ACHIRAL
Molecular Formula C19H22N4O2S.2ClH.2H2O
Molecular Weight 479.421
Optical Activity NONE
Defined Stereocenters 0 / 0
E/Z Centers 0
Charge 0

SHOW SMILES / InChI
Structure of TELENZEPINE DIHYDROCHLORIDE DIHYDRATE

SMILES

O.O.Cl.Cl.CN1CCN(CC(=O)N2C3=C(C)SC=C3C(=O)NC4=C2C=CC=C4)CC1

InChI

InChIKey=FGZLYNOZVXLZSO-UHFFFAOYSA-N
InChI=1S/C19H22N4O2S.2ClH.2H2O/c1-13-18-14(12-26-13)19(25)20-15-5-3-4-6-16(15)23(18)17(24)11-22-9-7-21(2)8-10-22;;;;/h3-6,12H,7-11H2,1-2H3,(H,20,25);2*1H;2*1H2

HIDE SMILES / InChI

Molecular Formula C19H22N4O2S
Molecular Weight 370.469
Charge 0
Count
Stereochemistry ACHIRAL
Additional Stereochemistry No
Defined Stereocenters 0 / 0
E/Z Centers 0
Optical Activity NONE

Molecular Formula ClH
Molecular Weight 36.461
Charge 0
Count
Stereochemistry ACHIRAL
Additional Stereochemistry No
Defined Stereocenters 0 / 0
E/Z Centers 0
Optical Activity NONE

Molecular Formula H2O
Molecular Weight 18.0153
Charge 0
Count
Stereochemistry ACHIRAL
Additional Stereochemistry No
Defined Stereocenters 0 / 0
E/Z Centers 0
Optical Activity NONE

Telenzepine is a selective muscarinic M1 receptor antagonist that was studied for selective inhibition of gastric acid secretion. Telenzepine was used in clinical trials in patients with acute duodenal ulcer, where was found that once daily administration of 3 mg in the evening must be regarded as the optimal dosage regimen of telenzepine. However, the preregistration for peptic ulcer in Germany was discontinued. In addition, the drug was studied in patients with nocturnal asthma. It was shown that telenzepine via the oral route at a dose of up to 5 mg was not effective in preventing nocturnal asthma.

Approval Year

Targets

Targets

PubMed

PubMed

TitleDatePubMed
[Beneficial effect of galantamine on sensory information-processing deficits].
2010-10
Formation and dissociation of M1 muscarinic receptor dimers seen by total internal reflection fluorescence imaging of single molecules.
2010-02-09
Differential effects of M1 and 5-hydroxytryptamine1A receptors on atypical antipsychotic drug-induced dopamine efflux in the medial prefrontal cortex.
2009-09
Galantamine improves apomorphine-induced deficits in prepulse inhibition via muscarinic ACh receptors in mice.
2009-01
Secretion from acinar cells of the exocrine pancreas: role of enteropancreatic reflexes and cholecystokinin.
2009-01
Effect of muscarinic receptor agonists xanomeline and sabcomeline on acetylcholine and dopamine efflux in the rat brain; comparison with effects of 4-[3-(4-butylpiperidin-1-yl)-propyl]-7-fluoro-4H-benzo[1,4]oxazin-3-one (AC260584) and N-desmethylclozapine.
2008-10-31
Development of a homogeneous high-throughput live-cell G-protein-coupled receptor binding assay.
2008-09
Muscarinic receptor M1 and phosphodiesterase 1 are key determinants in pulmonary vascular dysfunction following perinatal hypoxia in mice.
2008-07
Acetylcholine mediates the release of IL-8 in human bronchial epithelial cells by a NFkB/ERK-dependent mechanism.
2008-03-17
Modulation of long-term potentiation by individual subtypes of muscarinic acetylcholine receptor in the rat dentate gyrus.
2008
AC260584 (4-[3-(4-butylpiperidin-1-yl)-propyl]-7-fluoro-4H-benzo[1,4]oxazin-3-one), a selective muscarinic M1 receptor agonist, increases acetylcholine and dopamine release in rat medial prefrontal cortex and hippocampus.
2007-10-31
Muscarinic preferential M(1) receptor antagonists enhance the discriminative-stimulus effects of cocaine in rats.
2007-10
Effects of muscarinic M1 receptor blockade on cocaine-induced elevations of brain dopamine levels and locomotor behavior in rats.
2007-04
Segment-dependent expression of muscarinic acetylcholine receptors and G-protein coupling in the equine respiratory tract.
2007-02
Muscarinic acetylcholine receptor-dependent induction of persistent synaptic enhancement in rat hippocampus in vivo.
2007-01-19
N-desmethylclozapine, a major metabolite of clozapine, increases cortical acetylcholine and dopamine release in vivo via stimulation of M1 muscarinic receptors.
2005-11
M3 subtype of muscarinic receptors mediate Ca2+ release from intracellular stores in rat prostate neuroendocrine cells.
2005-04
Effect of muscarinic receptor blockade on canine gastric tone and compliance in vivo.
2005-04
Muscarinic modulation of nitrergic neurotransmission in guinea-pig gastric fundus.
2004-04
Muscarinic acetylcholine receptors potentiate the GABAergic transmission in the developing rat inferior colliculus.
2003-09
Miniaturization of fluorescence polarization receptor-binding assays using CyDye-labeled ligands.
2003-08
Cholinergic modulation of memory in the basolateral amygdala involves activation of both m1 and m2 receptors.
2003-05
PMA decreases the proliferation of retinal cells in vitro: the involvement of acetylcholine and BDNF.
2003-01
Cholinergic modulation of basal and amphetamine-induced dopamine release in rat medial prefrontal cortex and nucleus accumbens.
2002-12-20
Inhibition of field stimulation-induced contractions of rabbit vas deferens by muscarinic receptor agonists: selectivity of McN-A-343 for M1 receptors.
2001-04
Interleukin-2 and interleukin-4 increase the survival of retinal ganglion cells in culture.
2001-01-22
Distinct muscarinic receptors enhance spontaneous GABA release and inhibit electrically evoked GABAergic synaptic transmission in the chick lateral spiriform nucleus.
2001
Characterization of the muscarinic receptor subtype mediating pilocarpine-induced tremulous jaw movements in rats.
1999-01-01
Assessment of the muscarinic receptor subtypes involved in pilocarpine-induced seizures in mice.
1994-02-28
Correlation of brain levels of 9-amino-1,2,3,4-tetrahydroacridine (THA) with neurochemical and behavioral changes.
1989-11-28
The existence of stable enantiomers of telenzepine and their stereoselective interaction with muscarinic receptor subtypes.
1989-04

Sample Use Guides

120 patients with endoscopically proven, florid duodenal ulcer were treated with either 1.5 mg, 3 mg or 5 mg telenzepine once daily at bedtime (40 patients per dose group).
Route of Administration: Oral
Substance Class Chemical
Created
by admin
on Wed Apr 02 10:14:50 GMT 2025
Edited
by admin
on Wed Apr 02 10:14:50 GMT 2025
Record UNII
FC9LY2D3RS
Record Status Validated (UNII)
Record Version
  • Download
Name Type Language
TELENZEPINE DIHYDROCHLORIDE DIHYDRATE
Common Name English
TELENZEPINE HYDROCHLORIDE HYDRATE [JAN]
Preferred Name English
Code System Code Type Description
FDA UNII
FC9LY2D3RS
Created by admin on Wed Apr 02 10:14:50 GMT 2025 , Edited by admin on Wed Apr 02 10:14:50 GMT 2025
PRIMARY
KEGG
D11098
Created by admin on Wed Apr 02 10:14:50 GMT 2025 , Edited by admin on Wed Apr 02 10:14:50 GMT 2025
PRIMARY
PUBCHEM
134822646
Created by admin on Wed Apr 02 10:14:50 GMT 2025 , Edited by admin on Wed Apr 02 10:14:50 GMT 2025
PRIMARY
Related Record Type Details
PARENT -> SALT/SOLVATE